HomeCompareQLGN vs GBDC

QLGN vs GBDC: Dividend Comparison 2026

QLGN yields 62.31% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.12M in total portfolio value· pulled ahead in Year 7
10 years
QLGN
QLGN
● Live price
62.31%
Share price
$3.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$729.0K
Annual income
$175,361.30
Full QLGN calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — QLGN vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQLGNGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QLGN + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QLGN pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QLGN
Annual income on $10K today (after 15% tax)
$5,295.95/yr
After 10yr DRIP, annual income (after tax)
$149,057.10/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,834,066.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QLGN + GBDC for your $10,000?

QLGN: 50%GBDC: 50%
100% GBDC50/50100% QLGN
Portfolio after 10yr
$10.79M
Annual income
$8,313,047.57/yr
Blended yield
77.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

QLGN
No analyst data
Altman Z
-5.6
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QLGN buys
0
GBDC buys
0
No recent congressional trades found for QLGN or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQLGNGBDC
Forward yield62.31%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$729.0K$20.85M
Annual income after 10y$175,361.30$16,450,733.83
Total dividends collected$608.8K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: QLGN vs GBDC ($10,000, DRIP)

YearQLGN PortfolioQLGN Income/yrGBDC PortfolioGBDC Income/yrGap
1$16,931$6,230.53$12,492$1,791.70+$4.4KQLGN
2$27,974$9,858.52$16,527$3,160.58+$11.4KQLGN
3$45,156$15,223.51$23,588$5,904.90+$21.6KQLGN
4$71,283$22,966.14$37,141$11,901.65+$34.1KQLGN
5$110,155$33,882.50$66,205$26,463.38+$44.0KQLGN
6$166,800$48,934.07$137,452$66,612.65+$29.3KQLGN
7← crossover$247,726$69,249.85$342,372$195,298.53$94.6KGBDC
8$361,186$96,119.21$1,053,292$686,954.33$692.1KGBDC
9$517,443$130,974.20$4,111,439$2,984,416.95$3.59MGBDC
10$729,026$175,361.30$20,849,974$16,450,733.83$20.12MGBDC

QLGN vs GBDC: Complete Analysis 2026

QLGNStock

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Full QLGN Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this QLGN vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QLGN vs SCHDQLGN vs JEPIQLGN vs OQLGN vs KOQLGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.